VAR2 Pharmaceuticals is attending the American Association Cancer Research Annual Meeting taking place in California between April 17 and 22.

Our Executive Chairman of the Board and company co-founder Mads Daugaard will be on site and presenting a poster (CT112) on the clinical validation of our anti-oncofetal chondroitin sulfate Vartumabs in our ongoing Phase 0 PET/CT study.

 We are looking forward to meeting old and new partners to discuss synergies around our lead ADC based on our first-in-class antibodies against oncofetal CS and how to move these to clinical practice.